According to a new analysis, PLND does not impact recurrence-free survival but may reduce metastatic spread in intermediate- and high-risk prostate cancer. The benefit of PLND is most evident in ...

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...

Analysis of the results of intravesical perfusion therapy combined with immediate or non-immediate hematoporphyrin intravesical perfusion photodynamic therapy (PDT) after TURBT for NMIBC. This is an ...

Right Pelvic Lymphocele Investigators have explored various strategies to prevent lymphoceles from forming. Most prostatectomies are now being done with concomitant lymphadenectomy. A few factors are ...

Preoperative (left; top and bottom) and postoperative PSMA-PET/CT images (right; top and bottom) demonstrate the successful removal of two positive pelvic lymph nodes in the radioguided surgical ...

N1 Single lymph node metastasis, 2 cm or less in greatest dimension N1 Single regional lymph node metastasis in the true pelvis (hypogastric, obturator, external iliac or presacral lymph node) N2 ...

Using real-world data, a team of U.S.-based investigators analyzed survival outcomes among an independent cohort of patients with metastatic urothelial cancer (UC) treated with immune checkpoint ...

Clinical node involvement on preoperative PSMA-PET predicts radiographic recurrence for pN1 prostate cancer patients following RP/PLND.

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...